Abstract 4672
Background
KRAS, NRAS and BRAF mutation testing for metastatic colorectal cancer (mCRC) is essential to guide treatment and prognostication. Multiple gene profiling assays are available, each with differing tumour sample size/quality requirements and turnaround time (TAT). Many UK hospitals send samples to off-site labs for profiling. A rapid TAT is desirable to plan appropriate chemotherapy +/- biologics from cycle one, as well as providing certainty and satisfaction for patients and clinicians.
Methods
This study was conducted at 2 UK tertiary cancer centres (University College London Hospital and Mount Vernon Hospital), comparing a pathway where gene profiling of mCRC was performed off-site using an NGS platform versus on-site testing using the Idylla platform (Biocartis, Mechelen, Belgium). Up to 50 patients were included in each group with 8 of the Idylla tests being used for samples that had failed with the NGS platform.
Results
Mutational profiling results for the whole cohort that were successfully tested (n = 84) showed 26% (22/84) were wildtype for KRAS/NRAS/BRAF, 62% (52/84) KRAS mutated, 2% (2/84) NRAS mutated, 10% (8/84) BRAF mutated. The median TAT in days (median, interquartile range (IQR)) of the on-site Idylla pathway was shorter than the off-site NGS pathway (4, 1 - 6 vs. 15, 13-17; p = <0.0001). In the off-site group median time from request to receipt of sample was 3 days (IQR 2 - 5) and median time from receipt to result was 10 days (IQR 9 - 13). Test failure rate was significantly higher with the NGS test (30%, 15/50) compared to the Idylla test (2%, 1/50) (p = 0.0001). 8 samples that had failed testing with the NGS platform, due to insufficient/low quality of sample, were all successfully tested with the Idylla platform.
Conclusions
For gene profiling of mCRC, on-site testing with the Idylla platform significantly shortened the TAT, lowered failure rate and was able to test more sub-optimal samples compared to off-site NGS testing. Updated results integrating these data with tumour location, MMR status and treatment outcomes will be presented at ESMO 2019.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Biocartis provided the Idylla test kits for this study without charge.
Disclosure
N. Bhuva: Honoraria (self), supported in attending international meetings: Amgen; Honoraria (self), supported in attending international meetings: Bristol-Myers Squibb. K. Shiu: Honoraria (self), Advisory / Consultancy, supported in attending lectures and conferences: Roche; Honoraria (self), Advisory / Consultancy, supported in attending lectures and conferences: Merck Group; Honoraria (self), Advisory / Consultancy, supported in attending lectures and conferences: Servier; Honoraria (self), Advisory / Consultancy, supported in attending lectures and conferences: Guardant Health. All other authors have declared no conflicts of interest.
Resources from the same session
3353 - Results of the 3rd interim analysis of C-Patrol: A non-interventional study on olaparib in German routine clinical practice
Presenter: Jalid Sehouli
Session: Poster Display session 2
Resources:
Abstract
740 - A real-world analysis of the treatment of advanced ovarian cancer with PARPIs
Presenter: Alejandra Martinez de Pinillos
Session: Poster Display session 2
Resources:
Abstract
5867 - Incidence of tumour BRCA1/2 variants in relapsed, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer
Presenter: Robert Morgan
Session: Poster Display session 2
Resources:
Abstract
2966 - Frequency of mutations in 21 hereditary breast and ovarian cancer susceptibility genes among 882 high-risk individuals
Presenter: Jihong Liu
Session: Poster Display session 2
Resources:
Abstract
1687 - BRCA testing of 1,284 Brazilian patients for hereditary breast and ovarian cancer in a routine diagnostic setting
Presenter: Fernanda Milanezi
Session: Poster Display session 2
Resources:
Abstract
3162 - A multi-center integrative study on cancer predisposition genes in Chinese patients with epithelial ovarian carcinoma
Presenter: Changbin Zhu
Session: Poster Display session 2
Resources:
Abstract
5993 - Incidental Early Occult Ovarian Cancer after Risk-Reducing Salpingo-Oophorectomy in BRCA1/2 Mutation Carriers followed in a Community Public Hospital
Presenter: Begona Grana Suarez
Session: Poster Display session 2
Resources:
Abstract
5334 - Response to chemotherapy in ovarian cancer (OC) patients with or without prior breast cancer (BC), stratified by BRCA mutation (BRCAm) status
Presenter: Angela George
Session: Poster Display session 2
Resources:
Abstract
4565 - Advanced ovarian cancer: is residual disease after debulking surgery affected by genetics factors involved in angiogenesis and immunity pathways?
Presenter: Michele Bartoletti
Session: Poster Display session 2
Resources:
Abstract
3251 - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study
Presenter: Fabrice Lecuru
Session: Poster Display session 2
Resources:
Abstract